NF-κB signalling initiated by different receptors requires the formation of proximal protein-protein interactions that are often receptor specific, but ultimately converge in the activation of the IκB kinase (IKK) complex, which mediates phosphorylation of the inhibitory IκB protein leading to its K48-polyubiquitination and degradation by the proteasome [ 20].
Lobular tumours are more often receptor positive than ductal tumours (Chu and Anderson, 2002), and it would therefore seem obvious that overall, lobular tumours should be associated with hormonal factors, but once receptor status has been taken into account, it is not clear whether any of the histological subtypes should be more or less associated with hormonal factors.
This process is often receptor-mediated, and ultimately results in internalization of the pathogen into a phagosome via a complex sequence of events involving receptor clustering, kinase activation, remodeling of the actin cytoskeleton and an increase of membrane traffic (see [1], [2], [3] for review).
Aptamers typically act as ligands for proteins, often receptors, in either the intra- or extracellular environment, allowing the aptamer to affect the functionality of downstream effectors.
True to the molecular signature of basal-like tumors [ 2, 3, 16], breast-ACC is often estrogen receptor (ER -negative and progER -negativeeptor (PR)-negandve [ 17- 20] and does not exprogesteroneneu [ 18, 20, 21].
Most often, the receptor for an intercellular messenger is a transmembrane receptor with the cell membrane as border between inter- and intracellular pathways.
In contrast, the length of an unbound interval depends only on how often the receptor gets hit and is thus more purely a measure of the concentration of molecules.
Unexpected and often unexplained receptor activities are observed for ER, AR, and, more recently, GR.
The target, often a receptor, is (covalently) immobilized on a column.
Amidation of the carboxyl terminal of many peptides is essential for full biological potency, often increasing receptor binding and stability.
Breast cancers in mutation carriers were more often hormone receptor positive compared with cancers in noncarriers (94.5% vs 80.7%).
